To date, there is no national organized cervical cancer screening program in France. Since 1990, four departments—Bas-Rhin, Haut-Rhin, Isère, and Martinique—have organized screening for this cancer. Each screening management body has established its own specific organizational structure. Alsace (Bas-Rhin and Haut-Rhin) invites women aged 25 to 65 who have not had a Pap smear in the past three years. The managing body collects the results of all Pap smears in the region. Isère invites all women aged 50 to 74 every two years and collects results only from Pap smears performed as part of the organized screening program. Martinique invites all women aged 25 to 65 every three years, while allowing women aged 20 to 24 to undergo organized screening Pap smears upon a healthcare provider’s request. This report presents the results of the first centralized epidemiological evaluation of the four programs still in operation. The evaluation covers the last complete screening campaign conducted between 2003 and 2005. Differences in program organization made it difficult to compare their results. Despite relatively low participation in organized screening, the percentage of women who had at least one Pap smear over a three-year period (coverage) is higher than the national average. The quality of cervical smear specimens, as judged by the percentage of unevaluable smears, is very good in both mainland France and Martinique. Similarly, the quality of Pap smear interpretation, as judged by the percentage of ASC-US smears, is high. The collection of data on the prevalence of precancerous and cancerous lesions has enabled the evaluation of the program’s effectiveness and the identification of an epidemiological context for cervical pathology that differs in Martinique compared to mainland France. As part of efforts to improve access to cervical cancer screening in France, local organized screening programs, operating under a common protocol, can make a significant contribution. With the introduction of HPV vaccines into the market, these programs will be a key component in monitoring the vaccine’s impact on precancerous and cancerous lesions. (R.A.)